Literature DB >> 33442930

Incidence of ablation-induced esophageal injury associated with high-power short duration temperature-controlled pulmonary vein isolation using a specialized open-irrigated ablation catheter: A retrospective single-center study.

Robert Piringer1, Thomas Deneke2, Borek Foldyna3,4, Kai Sonne2, Karin Nentwich2, Elena Ene2, Sebastian Barth2, Ulrich Lüsebrink5, Artur Berkovitz2, Philipp Halbfass2,5.   

Abstract

INTRODUCTION: To evaluate short-term efficacy and incidence of ablation-induced endoscopically detected esophageal injury in patients undergoing high-power, short-duration (HPSD) pulmonary vein isolation using a novel irrigated radiofrequency ablation catheter and ablation generator setup. METHODS AND
RESULTS: Atrial fibrillation (AF) patients, who underwent AF ablation using an irrigated radiofrequency ablation catheter specifically designed for a HPSD ablation approach (50 W, with a target Ablation Index of 350 at posterior wall), received postablation esophageal endoscopy after ablation. In total 45 consecutive patients (67 ± 10 years; 58% male; 42% paroxysmal AF) undergoing AF ablation using a specialized ablation catheter (QDOT) were included in the study. Thirty-one of 45 patients (69%) underwent a first-time pulmonary vein isolation (Group 1, 67 ± 11 years; 55% male; 48% paroxysmal AF). Fourteen patients (31%) underwent a redo AF procedure (Group 2, 66 ± 8 years; 64% male; 29% paroxysmal AF). Patients undergoing first-time pulmonary vein isolation were included in the final analysis. In these patients an endoscopically detected esophageal lesion (EDEL) was detected in 5 of 31 (16%) patients (erosion n = 2, ulcer n = 3). Mean contact force at posterior wall ablation sites was significantly lower in patients with postprocedural EDEL compared with patients without EDEL (11.9 ± 0.8 g vs. 15.6 ± 4.7 g).
CONCLUSION: PVI using a specialized high-power ablation catheter in conjunction with a HPSD ablation approach results in a 16% incidence of EDEL in first AF ablation candidates. Future studies evaluating high-power short duration ablation strategies should include esophageal endoscopy to estimate the risk of clinically relevant esophageal complications.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  QDOT ablation catheter; atrial fibrillation; endoscopically detected esophageal lesion; high-power short duration ablation; pulmonary vein isolation

Year:  2021        PMID: 33442930     DOI: 10.1111/jce.14883

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  4 in total

1.  [Pulmonary vein isolation using radiofrequency ablation].

Authors:  Leon Iden; Sonia Busch; Daniel Steven; Roland R Tilz; Dong-In Shin; K R Julian Chun; Heidi Estner; Felix Bourier; David Duncker; Philipp Sommer; Andreas Metzner; Tilman Maurer; Nils-Christian Ewertsen; Henning Jansen; Andreas Rillig; Victoria Johnson; Till Althoff
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-07-26

2.  Ablation index-guided 50W radiofrequency ablation for left atrial posterior wall isolation in atrial fibrillation.

Authors:  Wern Yew Ding; Lilith Tovmassian; Cedric Bierme; Nikola Kozhuharov; Richard L Snowdon; Dhiraj Gupta
Journal:  Indian Pacing Electrophysiol J       Date:  2022-05-26

3.  Lesion size and adjacent tissue damage assessment with high power and short duration radiofrequency ablation: comparison to conventional radiofrequency ablation power setting.

Authors:  Yoshinari Enomoto; Keijiro Nakamura; Rina Ishii; Yasutake Toyoda; Masako Asami; Takahito Takagi; Hikari Hashimoto; Hidehiko Hara; Kaoru Sugi; Masao Moroi; Masato Nakamura
Journal:  Heart Vessels       Date:  2021-03-19       Impact factor: 2.037

4.  Very high-power short-duration temperature-controlled ablation versus conventional power-controlled ablation for pulmonary vein isolation: The fast and furious - AF study.

Authors:  Roland Richard Tilz; Makoto Sano; Julia Vogler; Thomas Fink; Roza Saraei; Vanessa Sciacca; Bettina Kirstein; Huong-Lan Phan; Sascha Hatahet; Lisbeth Delgado Lopez; Anna Traub; Charlotte Eitel; Michael Schlüter; Karl-Heinz Kuck; Christian-Hendrik Heeger
Journal:  Int J Cardiol Heart Vasc       Date:  2021-07-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.